Company ProfilePremium

Aprogen Inc. (formerly Aprogen KIC Inc.)

Company Profile Analysis

Ticker: 007460.KS주식회사 에이프로젠

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aprogen Inc. - Company showcase

Year Founded & Workforce

1971

625 Employees

Aprogen Inc. logo

Aprogen Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aprogen Inc. Overview

Aprogen Inc. is a loss-making Korean biopharmaceutical holding company. It sits on top of a 55-year-old listed industrial shell, the former KIC, and its strategy rests on one technological claim: perfusion (continuous) cell-culture manufacturing at the Osong plant can produce monoclonal antibodies at a fraction of the cost of fed-batch competitors. Its lead asset is AP063, a trastuzumab (Herceptin) biosimilar. In 2026 both the EMA and the FDA indicated that AP063 could proceed toward approval without a confirmatory Phase 3, which shifts the critical path to process-validation (PPQ) manufacturing and dossier filing. Behind AP063 sit adalimumab and rituximab biosimilars, an osteoarthritis biologic (AP209), an in-licensed anti-VISTA immuno-oncology antibody (PMC-309) and, through listed subsidiary Apton, the Phase 2-complete mobiliser burixafor (GPC-100). Consolidated revenue (KRW 118bn in FY2025) still leans heavily on non-pharma businesses: hardfacing, semiconductor-equipment parts, geothermal engineering and insulation. The group depends on repeated intra-group equity and convertible-bond financing.


What the company does

Aprogen operates at two levels.

Parent level. The listed entity is a bio R&D company and, since January 2025, a statutory holding company. It owns and directs the group's biologics pipeline: biosimilars and novel antibodies or fusion proteins. It also retains legacy KIC industrial activities, chiefly hardfacing (wear-resistant overlay cladding) and insulation for heavy-industry plant [S4][S38].

Group level. Consolidated revenue includes several listed and unlisted subsidiaries:

Aprogen Biologics: (KOSPI: 003060; 56.9% owned): pharmaceutical sales, Osong plant CMO/CDMO, and semiconductor-equipment parts through its control of N2Tech.

Aptochrome: (formerly AP Healthcare; 71.7%): pharmaceutical distribution.

Apton: (KOSDAQ: 270520; formerly GeoLit Energy, then Apt Neuroscience; 31.6%): geothermal/renewable-energy engineering plus new-drug development.

KIC Industrial Machinery (Zhangjiagang) Co: (China; 100%).

[S2][S27][S33]

Company's own description

The June 2025 IR presentation describes the company as a biotech that develops commercially attractive biologics on the strength of world-class technology. Its stated main business is the development, manufacture and sale of biosimilars and novel biologics (bispecific antibodies and dual-receptor fusions). It highlights:

  • its 2020 designation as Korea's first bio "unicorn";

  • a claimed lowest-in-world manufacturing cost; and

  • a proprietary, internationally registered bispecific-antibody platform.

[S3]

In November 2025 management restated strategy as three pillars: biosimilars (exploiting regulatory easing), innovative new drugs (immuno-oncology and osteoarthritis), and "hybrid" CMO. [S31]

Business and revenue model

Revenue streamModelStatus (Oct 2026)Source
Biosimilar licensing / commercial supplyLicensing of sales rights to regional distributors plus supply from Osong. The company targets about a 50% price discount versus competitors.Pre-revenue for AP063, AP096 and AP056. Infliximab biosimilar GS071 is approved in Japan (2017); its current commercial contribution is not disclosed.[S3][S19]
Novel drugsEarly licence-out (L/O) or co-development with global pharmaAP209 is entering Phase 1; PMC-309 is in Phase 1a/1b (Australia); GPC-100 (via Apton) is planning Phase 3[S3][S29][S34]
CMO / CDMOFee-for-service drug substance and drug product manufacturing at OsongThe plant was approved by Korea's Ministry of Food and Drug Safety (MFDS) as a specialised biologics CMO in June 2024. One molecule was won (DS+DP) and three were under negotiation as of mid-2025.[S3][S25]
Pharmaceutical sales / distributionTrading marginRevenue-generating (43% of the 2Q26 mix with all pharma combined)[S4]
HardfacingIndustrial service/product (legacy KIC)Revenue-generating (23% of mix)[S4]
Semiconductor-equipment partsManufacturing (N2Tech)Revenue-generating (22% of mix)[S4][S27]
Renewable energy (geothermal)Engineering (Apton)Revenue-generating (10% of mix)[S4][S34]
InsulationIndustrial (legacy KIC; LNG/plant)Revenue-generating (3% of mix)[S4]

Product versus service versus licensing mix: on the 2Q26 mix, roughly 43% is pharmaceutical (mostly product and distribution sales) and about 58% is industrial product or engineering revenue. The rows sum to 101% because of source rounding. Licensing revenue is not separately disclosed and appears immaterial.

Value-chain position, customers and end-markets

AreaCustomers / end-markets
Biosimilar partnersRegional pharmaceutical distributors (Europe, US)
CDMO clientsBiopharma sponsors, including European companies and group affiliates (e.g. Apton's Parkinson's programme)
Therapeutic areasOncology (HER2+ breast cancer, haematological malignancy), autoimmune/inflammatory disease, osteoarthritis, neurodegeneration
Industrial customersSteel, petrochemical, shipbuilding, power-generation and LNG plant operators (KIC heritage)
Semiconductor customersSemiconductor-equipment supply chain (N2Tech)

In biologics, Aprogen is vertically integrated from cell-line development through drug substance and drug product. Its stated strength is the upstream step, where it combines high-titre cell lines with perfusion culture. It relies on partners for clinical execution (e.g. Syneos as CRO for the AP063 Phase 3) and for commercial distribution [S3][S19].

[S25][S38]

Independent characterisation

Aprogen is best understood as a high-burn, pre-commercial biosimilar platform bolted onto a listed industrial shell. It is surrounded by a web of listed affiliates whose capital raises circulate within the group.

The economic thesis is real and specific. Perfusion at 2,000L working volume is claimed to yield 92–200 kg of antibody per batch, against roughly 30–60 kg for a 12,000–15,000L fed-batch run. If that holds at commercial scale under cGMP, it supports aggressive price-led entry into mature biosimilar molecules.

The execution record is weak, however:

  • no Western approvals after more than two decades;

  • operating losses of KRW 87–119bn every year from FY2021 to FY2025;

  • market value down well over 90% from 2022 levels; and

  • persistent press scrutiny of related-party funding loops.

[S1][S3][S27][S35]

Strategy

Stated corporate strategy (paraphrased from the June 2025 IR deck and November 2025 statement)

The vision is to become a company with world-class commercial competitiveness from R&D through manufacturing, on four tracks:

  1. Accelerate biosimilar development and approval.

  2. Co-develop or out-license novel drug projects.

  3. Open global distribution channels for commercialisation.

  4. Push the CDMO business in earnest.

[S3]

Within this, management frames "three engines" (CDMO, biosimilar rights licensing, novel drugs) and 13 concurrent projects: 6 CDMO, 3 licensing and 4 novel-drug projects. The deck aspires to a "Global Top Tier for CDMO" and indicates an expected turnaround around 2027 [S3].

The November 2025 restatement narrowed this to biosimilars (leveraging FDA/EMA streamlining), innovative drugs (PMC-309, AP209) and hybrid CMO [S31].

Strategic initiatives (last 24 months)

DateInitiativeDetailSource
Oct–Nov 2024FDA Type 2 BPD meeting on AP063 PPQSought acceptance of a reduced PPQ data package using the sub-batch approach[S20]
Dec 2024 – Jan 2025Neurodegeneration entry via GeoLit Energy (now Apton)17.22% stake; Parkinson's patents (KRW 5.4bn); plan to reach at least 36.3% via a KRW 45bn CB[S24]
1 Jan 2025Holding-company conversionFair Trade Act holding-company structure[S7]
Mar 2025Diversification into semiconductor partsAprogen Biologics buys the Montana Fund No. 72 vehicle controlling N2Tech[S26][S27]
Jun 2025Crypto-asset strategy at Apt NeuroscienceUS subsidiary Aptelos to invest in digital assets[S43]
Aug 2025Immuno-oncology in-licensingPMC-309 from PharmAbcine[S29]
Aug 2025Consolidated AP Healthcare controlStake raised to 71.66%[S28]
Nov 2025AP063 clinical strategy resetPhase 3 replaced by quality and PK-centric package; about KRW 130bn savings claimed[S20]
Feb 2026Balance-sheet clean-up at subsidiaries15:1 (Aprogen Biologics) and 20:1 (Aptochrome) capital reductions to offset deficits[S8]
May 2026Regulatory de-risking of AP063EMA and FDA alignment on no Phase 3[S21][S22]
Mid-2026AP209 first-in-humanMFDS approval for a 46-patient study; IRB at Kyung Hee University Hospital[S37]
Jul–Sep 2026Cell-therapy booster and obesityApton's KRW 10bn into GPCR; global rights to GPC-100; Aprogen clinical team assembled to run Phase 3[S33][S34]

ESG and sustainability commitments: none disclosed.

Cost programmes: the only explicit programme is the 2022–2023 emergency management and voluntary retirement scheme [S13]. No quantified cost targets were identified.

Medium-term targets and guidance

The company has issued no formal financial guidance.

Historic aspirational statements have not been met. In 2020, group materials projected biosimilar revenue surpassing KRW 1 trillion by 2026, whereas actual FY2025 revenue was KRW 118bn [S9][S1]. In January 2024 the company cited an internal valuation of KRW 2.6tn, versus a market capitalisation of roughly KRW 0.05–0.07tn in 2026 [S15][S4].

Pipeline timing statements:

  • AP096: trials to 2027 and launch as early as 2028, under the 2024 co-funding plan [S18].

  • GPC-100: Phase 3 results targeted within about 2 years of start [S34].

  • AP063: BLA to follow completion of PPQ data; no date given [S21].

Products & Services

Biosimilars (Pharmaceuticals / R&D)

ProductReference product (molecule)IndicationsStage (latest verified)Target customerKey specifications / capabilitiesPricing modelSource
AP063Herceptin (trastuzumab)HER2+ early and metastatic breast cancerUS Phase 1 completed (2019–20). Global Phase 3 (APRILIAH, 720 patients) launched 2023 and ended early in April 2025. EMA Scientific Advice and an FDA pre-BLA meeting (May 2026) indicate approval can be pursued on analytical plus PK/immunogenicity data without Phase 3. Next step: PPQ manufacturing, then BLA/MAA.Oncology payers and hospitals in EU/US via distribution partners92 kg per 2,000L perfusion batch; 8 batches/yr gives 736 kg/yr, which the company equates to about 40% of world consumption. FDA/EMA previously accepted each of 6 purification sub-batches as an independent DS batch.Not disclosed; strategy is deep discount (target about 50% below competitors)[S3][S19][S20][S21][S22][S23]
AP096Humira (adalimumab)Rheumatoid arthritis, Crohn's disease and other autoimmune conditionsClinical material produced (Nov 2024 run harvested 201.5 kg in one perfusion run); clinical programme in preparation. A 2024 plan targeted trials to 2027 and launch as early as 2028.Autoimmune market via partners156 kg/batch, 8 batches/yr, 1,248 kg/yr; the company claims this exceeds 100% of world consumptionNot disclosed. AP Healthcare co-funds KRW 70bn in return for a share of commercial proceeds.[S3][S18]
AP056Rituxan (rituximab)Non-Hodgkin lymphoma, CLL, autoimmune diseaseClinical material production. The IR deck says "preparing" on one slide and "completed" on another (inconsistent).Oncology / autoimmune102 kg/batch, 7 batches/yr, 714 kg/yr (about 34% of world consumption claimed)—[S3]
GS071Remicade (infliximab)Autoimmune / inflammatory diseaseApproved in Japan (2017). US Phase 3 completed (2019–20). Commercial batch production from 2021. A global sales-rights contract was signed in 2014; counterparty not stated in the sources reviewed. Current sales contribution not publicly disclosed.Japanese market (via licensee)——[S3]
Avastin (bevacizumab) biosimilarAvastinOncologyListed in 2021 pipeline communications; current status not disclosed in 2025 materials———[S41]

Novel biologics (Pharmaceuticals / R&D)

AssetModalityIndicationStageNotesSource
AP209Dual-receptor Fc fusion per the IR deck; described elsewhere as a bispecific antibody (inconsistent descriptions)OsteoarthritisNon-clinical toxicology completed. MFDS clinical approval obtained in mid-2026 (46 patients). IRB submission to Kyung Hee University Hospital around August 2026.Licence-out or co-development discussions with global pharma reported[S3][S31][S37]
PMC-309Anti-VISTA monoclonal antibody (immune checkpoint)Advanced/metastatic solid tumoursPhase 1a/1b in Australia (67-patient target; study end expected 30 May 2028)In-licensed from PharmAbcine on 18 Aug 2025 (exclusive global R&D, commercialisation and manufacturing rights). Contract value undisclosed but at least 5% of Aprogen's FY2024 revenue. A Keytruda combination is planned.[S29][S31]
Fc-engineered antibodyFc-enhanced mAbTriple-negative breast cancerPreparing non-clinical DS—[S3]
Bispecific antibody #1BispecificAcute leukaemiaCell-line development; animal efficacy shown—[S3]
Bispecific antibody #2BispecificAcute leukaemiaMolecule optimisation—[S3]
ADC antibodyAntibody-drug conjugateAcute blood cancerListed as a licence-out item within the CDMO slide—[S3]
Bispecific manufacturing platformTechnology—Proprietary platform; patents registered in the US and other major countriesOffered as part of CDMO[S3]

Apton-held assets (consolidated subsidiary)

AssetDescriptionStageDeal termsSource
Burixafor (GPC-100)Rapid-acting mobiliser that moves haematopoietic stem cells and immune cells into peripheral blood. Reported to raise blood T-cell counts 7–10x or more within about an hour.US Phase 2 completed (multiple myeloma stem-cell mobilisation). FDA Orphan Drug Designation. Planned single US Phase 3 of about 120 patients, targeting results within about 2 years. Potential expansion to AML, sickle-cell disease and in-vivo CAR-T "booster" use.Global exclusive rights (26 Aug 2026): KRW 6.5bn to counterparty GPCRT; KRW 0.5bn upfront plus up to KRW 472bn in milestones to originator GPCR[S33][S34]
GPR75 programmeObesity target; antibody discovery with AbTherx; MTAs with two top-10 pharma companies reportedDiscoveryPriority negotiation rights via the GPCR investment[S33]
Parkinson's "Substance K"Endogenous metabolite and enhancers claimed to protect dopaminergic neurons in PD models; diagnostic patent filed November 2024PreclinicalThree patents acquired for KRW 5.4bn from Prof. Chung Jong-kyeong (SNU)[S3][S24]

Manufacturing services (CDMO/CMO)

Osong plant: perfusion process with switchable fed-batch; 4 × 2,500L plus 2 × 250L bioreactors; 4 purification lines.

Drug-product capacity per year: 6.4M lyophilised vials, 60M liquid vials, 80M prefilled syringes.

Additional capabilities: auto-injector assembly and secondary packaging.

Positioning and commercial status: pitched as "hybrid" CMO; first commercial award (one molecule, DS+DP) won and three more under negotiation per the June 2025 IR deck.

[S3][S31]

Non-pharma products and services

LineDescriptionShare of mix (H1 2026)Source
HardfacingWear-resistant overlay/cladding for heavy-industry components (KIC heritage). Product-level detail not disclosed.23%[S4][S38]
Semiconductor equipment partsN2Tech parts manufacturing. Product-level detail not disclosed.22%[S4][S27]
Renewable energyGeothermal heat-pump/energy engineering (Apton)10%[S4][S34]
InsulationInsulation for plant and LNG applications (KIC heritage)3%[S4][S38]

Financial Narrative

Basis. K-IFRS consolidated, KRW bn. FY2021 is shown on the reverse-acquisition (restated) basis used in DART-derived annual data and the June 2025 IR deck: revenue KRW 26.3bn, operating loss KRW 94.6bn [S1][S3].

Income statement

Sources: FY2021–FY2024 from the IR deck consolidated statements [S3]; FY2025 from the DART annual report [S1][S4].

Margins and growth are analyst calculations from the figures above.

Additional measures:

Revenue CAGR FY2021–FY2025: 45.5%. This is inflated by the restated FY2021 base.

Revenue CAGR FY2022–FY2025: 14.6%.

Revenue CAGR FY2023–FY2025: -11.5%.

  • Osong is a roughly KRW 600bn asset [S3], so D&A is likely material and EBITDA meaningfully less negative than operating income, but no figure is estimated.

  • Investing.com shows trailing-twelve-month EPS of KRW -3,636 on a post-consolidation share basis (Aug 2026) [S6].

Dividends per share: nil throughout FY2021–FY2025. No dividend yield is shown by data providers, consistent with accumulated deficits [S4].

Quarterly trajectory

[S1]

H1 FY2026 versus H1 FY2025:

  • Revenue: KRW 71.8bn versus KRW 50.9bn (+41.1%).

  • Operating loss: KRW 43.0bn versus KRW 46.4bn.

  • Net loss: KRW 70.4bn versus KRW 72.3bn.

Balance sheet

Source: IR deck consolidated statements [S3].

Notes on the balance sheet:

  • The deck's current and non-current asset subtotals do not sum to total assets in FY2023–FY2024. Total assets are shown as reported.

  • Third-party data imply equity was eroded by the FY2025 net loss of KRW 140.6bn, partly offset by capital raises. Valueline shows a price-to-book ratio of 1.11x at a KRW 67bn market cap (Aug 2026) [S5]; Butler shows 0.83–0.91x [S4].

  • Short/long debt split, goodwill and intangibles, working capital (FY2025): not publicly disclosed in retrieved sources.

Total assets at 31 Mar 2025: KRW 643.1bn [S3].

Cash flow

Qualitatively:

Dividends and buybacks: no dividends were paid. Treasury shares are about 5.97% of issued shares [S4], but no buyback programme was identified.

Funding pattern: cash burn of roughly KRW 90–120bn a year at operating level has been funded by repeated rights offerings, third-party placements and CBs placed with affiliates (G-Baise, Apton, Aprogen Biologics, N2Tech-linked funds) [S14][S17][S27][S30][S35].

Ratios

These are analyst calculations on average balances [S3]. The FY2022 ROE is distorted by the negative FY2021 opening equity.

Additional ratio notes:

Third-party ROE: Valueline reports -52.1% (as of 2Q26) [S5]; Butler reports -138.0% (trailing basis) [S4].

Not meaningful: ROIC, net debt/EBITDA and interest coverage, because operating income and EBITDA are negative.

Commentary: trends, inflections and drivers

FY2021 to FY2023: the revenue step-up is consolidation, not organic biosimilar sales. Revenue rose from KRW 26.3bn to KRW 150.6bn. The jump coincides with the July 2022 merger and the 2022 combination of Aprogen Pharmaceuticals with Aprogen Biologics, which brought pharmaceutical sales and the legacy KIC industrial businesses into the consolidated perimeter. Gross margin of about 23–24% in FY2023–FY2024 reflects distribution and industrial products, not biologic pricing.

FY2024 to FY2025: contraction. Revenue fell 21.4% to KRW 118.0bn, with the trough in Q1–Q2 FY2025 (KRW 24–27bn per quarter). The net loss widened to KRW 140.6bn, the worst on the restated series. Aprogen Biologics alone lost KRW 168.3bn net in FY2025 [S40].

FY2026 inflection in the top line only. Q1 and Q2 FY2026 revenue rose 35.8% and 47.0% YoY. The timing matches consolidation of N2Tech's semiconductor-parts business, which accounts for 22% of the mix. Operating losses remain stuck at KRW 20–22bn per quarter, so the cost base (R&D, Osong fixed costs, SG&A) has not been absorbed.

Structural cost. The parent's FY2025 payroll of KRW 15.7bn equals 40.6% of separate-basis revenue of KRW 38.6bn, up from 4.8% in FY2021 [S2]. The Osong plant runs largely for clinical and PPQ batches and small CMO jobs until commercial products arrive.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LevelEntityOwnershipFunctionFY2025 total assets (KRW Bn)FY2025 net income (KRW Bn)

Ultimate controller

G-Baise Co., Ltd. (unlisted; CEO Kang Seon-ju)

100% owned by Kim Jae-seop per 2020–2022 reporting

Pure holding company, management advisory

——

Listed parent

Aprogen Inc. (007460)

G-Baise 21.8%; related parties 36.63%

Bio R&D, holding company, legacy industrial

609.9 (FY2024)

-140.6 (consolidated)

Subsidiary

Aprogen Biologics (003060)

56.9%

Osong manufacturing/CMO, pharma sales, semiconductor parts (via N2Tech)

513.6-123.0

Subsidiary

Aptochrome (formerly AP Healthcare)

71.7%

Pharmaceutical distribution; co-funder of AP096

314.5-6.68

Subsidiary (de facto control)

Apton (270520; formerly GeoLit Energy / Apt Neuroscience)

31.6%

Geothermal engineering; Parkinson's programme; GPC-100

143.2-7.11

Subsidiary

KIC Industrial Machinery (Zhangjiagang) Co.

100%

Legacy industrial (China)

1.410.089

Grandchild (via Aprogen Biologics)

Montana New Technology Fund No. 72 → N2Tech (227950)

Fund owns 9.65% of N2Tech (largest holder)

Semiconductor-equipment parts

N2Tech: 159.3 (H1 2026)

—

Grandchildren (at holdco conversion)

Aprogen Pharma, Aprogen I&C, Aprogen Visionary, Vision Bros

————

Apton subsidiaries

Aptelos Inc. (California; 100% of Apton); GPCR Co. (largest shareholder after KRW 10bn investment)

as stated

Crypto-asset investment (announced 2025); CAR-T booster / GPR75 obesity

——

“—” = not publicly disclosed.

Segment Overview

SegmentH1FY2026

Pharmaceuticals (%)

43

Hardfacing (%)

23

Semiconductor equipment parts (%)

22

Renewable energy (%)

10

Insulation (%)

3

Segment Overview — Pharmaceuticals

SegmentH1FY2026

Pharmaceuticals (KRW Bn)

30.9

Hardfacing (KRW Bn)

16.5

Semiconductor equipment parts (KRW Bn)

15.8

Renewable energy (KRW Bn)

7.2

Insulation (KRW Bn)

2.2

Segment Overview (2)

SegmentH1FY2026

Pharmaceuticals (%)

62

Semiconductors (%)

33

Bio (%)

3

Other (%)

1

Results by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

56.565.287.467.473.2

Operating income (KRW Bn)

-3.8-5.4-57.5-52.8-60.4

Net income (KRW Bn)

9.25.6-115.3-105.0-168.3

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

26.378.3150.6150.1118.0

Gross profit (KRW Bn)

-0.46.235.834.9—

Operating income (KRW Bn)

-94.6-119.3-88.9-86.8-95.6

Net interest income/(expense) (KRW Bn)

-19.6-6.93.03.8—

FX and derivative gains/(losses) (KRW Bn)

-0.62.5-0.94.0—

Pre-tax income (KRW Bn)

-119.3-115.6-95.2-98.7—

Net income (KRW Bn)

-119.2-116.1-97.3-100.4-140.6

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

-1.77.923.823.3—

Operating margin (%)

-359.7-152.4-59.0-57.8-81.0

Net margin (%)

-453.2-148.3-64.6-66.9-119.2

Revenue growth YoY (%)

—197.792.3-0.3-21.4

Income Statement (Quarterly)

MetricQ1FY2024Q2FY2024Q3FY2024Q4FY2024Q1FY2025Q2FY2025Q3FY2025Q4FY2025Q1FY2026Q2FY2026

Revenue (KRW Bn)

38.135.636.839.626.724.235.631.536.335.5

Operating income (KRW Bn)

-18.0-17.7-22.0-29.1-22.5-23.9-22.3-26.9-20.6-22.4

Net income (KRW Bn)

-18.3-18.8-21.9-41.4-30.1-42.2-33.7-34.5-28.1-42.3

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024

Total assets (KRW Bn)

477.6599.9594.4609.9

Current assets (KRW Bn)

87.2168.5108.597.1

Cash and equivalents (KRW Bn)

15.943.135.737.1

Non-current assets (KRW Bn)

374.5388.3450.2475.7

Total liabilities (KRW Bn)

478.5138.9176.7169.8

Current liabilities (KRW Bn)

421.989.9125.6112.9

Non-current liabilities (KRW Bn)

56.548.951.156.9

Total equity (KRW Bn)

-0.8461.0417.7440.1

Total borrowings (KRW Bn)

429.781.0101.0100.3

Net debt (KRW Bn)

413.837.965.363.1

Net debt to equity (%)

—8.215.614.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024

ROE (%)

-50.5-22.1-23.4

ROA (%)

-21.5-16.3-16.7

Current ratio (x)

1.870.860.86

Borrowings to equity (x)

0.180.240.23

Liabilities to equity (%)

30.142.338.6

Asset turnover (x)

0.150.250.25

Revenue by Region

RegionFY2023FY2024FY2025

Total consolidated revenue (KRW Bn)

150.6150.1118.0

Data Point Details

Data pointValueDate

Share price

KRW 2,015

~26 Sep 2026

Share price

KRW 2,010

17 Sep 2026

Share price

KRW 2,365

27 Aug 2026

Share price

KRW 2,570

15 Aug 2026

Share price

KRW 2,465

2 Jul 2026

52-week range (Investing.com)

KRW 280 – 7,800

Aug 2026

Market capitalisation

KRW 50.0–67.0bn

Aug–Oct 2026

Shares outstanding

About 21–28M (sources inconsistent)

2026

Capital Markets

MetricFY2022FY2023FY2024FY2025

Dividends per share (KRW)

0000

Valuation Snapshot

MultipleValueComment

P/E

Not meaningful (losses)

Valueline -0.80x

P/B

0.83–1.11x

Varies by data date

EV/Sales

About 0.9–1.1x (analyst estimate)

Market cap of about KRW 55–67bn plus FY2024 net debt of KRW 63.1bn, over FY2025 revenue of KRW 118.0bn.

Capital Markets — Analyst consensus

ItemStatus

Analyst consensus

1 broker; target price KRW 1,410 (30–34% below the September 2026 price)

Dividend policy

No dividends; accumulated deficits

Buyback authorisation

None identified; treasury shares about 5.97%

Credit ratings (Moody's, S&P, Fitch)

None; no domestic agency rating identified

Analyst Conclusions

Management guidance and consensus

Formal financial guidance: none.

Consensus: one broker target of KRW 1,410; no consensus revenue or earnings estimates identified [S4].

Pipeline timing management has signalled: - AP063 BLA after PPQ (no date) [S21].

  • AP096 launch as early as 2028 under the 2024 plan [S18].

  • GPC-100 Phase 3 readout targeted about 2 years after start [S34].

  • Turnaround around 2027 [S3].

Bull case

  1. AP063 approval with a structurally lower cost base. The FDA and EMA no-Phase-3 alignment removes the largest development cost [S21][S22]. If perfusion economics hold in PPQ, Aprogen could undercut five or more incumbents profitably in a market worth about USD 2,893/g at reference pricing [S19].

  2. Osong as a monetisable asset. A roughly KRW 600bn cGMP plant with 3,000 kg/yr capacity [S3] trades inside a group valued at under KRW 70bn of equity [S4][S5]. A single meaningful CDMO contract, or a licence-out, could re-rate the stock.

  3. Late-stage optionality via Apton. An orphan-designated, Phase 2-complete mobiliser with a lean, roughly 120-patient Phase 3 [S34] offers a binary catalyst that is uncorrelated with biosimilars.

Bear case

  1. Persistent value destruction. Cumulative net losses of about KRW 574bn from FY2021 to FY2025 (sum of restated figures, [S1][S3]) and no commercial biosimilar revenue in the West after 26 years.

  2. Financing circularity and dilution. Capital is recycled among Aprogen, Aprogen Biologics, Apton, N2Tech and G-Baise through CBs, rights issues and loans [S27][S32][S35]. This erodes minority value and creates contagion risk if any node fails.

  3. Commoditised targets and execution risk. AP063 enters a trastuzumab market about 84% penetrated by biosimilars [S3] without a named distribution partner. The perfusion sub-batch PPQ approach still faces final regulatory review at BLA [S21].

Catalysts and monitorables (next 12 months)

  1. AP063 PPQ completion and BLA/MAA submission dates; any named US or EU commercialisation partner.

  2. GPC-100 FDA end-of-Phase-2 meeting outcome and Phase 3 first-patient-in.

  3. AP209 first-patient dosing at Kyung Hee University Hospital.

  4. Q3 FY2026 report (expected mid-November 2026): whether revenue growth from N2Tech consolidation continues and whether the operating loss narrows below KRW 20bn per quarter.

  5. Further CB or rights issues across group companies, CB conversions (overhang), and any capital reduction at the parent.

  6. Identity and intentions of Harvest Rose (14.18%).

  7. CDMO contract announcements for Osong.

  8. Regulatory or exchange actions related to group transactions.

Analyst verdict

Aprogen is two companies stapled together.

The asset with genuine value. Osong and the perfusion process may be one of Korea's more under-appreciated pieces of biologics manufacturing infrastructure. The 2026 regulatory signals on AP063 are the most concrete progress the company has made in years. The FDA and EMA have converged on allowing a trastuzumab biosimilar to proceed on analytical, PK and immunogenicity data alone. In that world the competitive variable is cost of goods, which is exactly the variable Aprogen has optimised for. The single 201.5 kg AP096 harvest is a real data point, not just a slide claim.

The structure that undermines it. The listed parent has lost about KRW 87–119bn at operating level every year since FY2021. More than half of its 2026 revenue now comes from hardfacing, semiconductor parts, geothermal engineering and insulation, businesses unrelated to the thesis. Capital is raised through affiliate-placed CBs and rights issues. Collateral and loans flow between subsidiaries and the founder-owned holding company, and the press has documented this repeatedly. Aspirational targets have consistently missed by an order of magnitude, from KRW 1tn of 2026 revenue promised in 2020 to KRW 118bn delivered in FY2025. Disclosure quality is low: no English reporting, no segment profitability in accessible form, and an unclear share count.

Investment framing. The equity is a deeply discounted, high-volatility option on two binary events: AP063 approval with a credible commercial partner, and GPC-100 Phase 3 progress. It is set against a high probability of continued dilution. On risk-adjusted terms, we would treat it as speculative and sell-side-neutral at best.

What would change the view. Three developments in sequence would warrant reassessment:

  1. a signed Western distribution agreement for AP063 with economics disclosed;

  2. a third-party CDMO contract of meaningful size; and

  3. a visible end to intra-group circular financing.

Until then, the governance discount is likely to persist regardless of scientific progress.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / historyEducationPrior roles

Kim Jae-seop

Chairman and CEO (representative director). Also co-CEO of Aprogen Biologics and CEO of Apton; inside director of G-Baise.

Founder (2000). Resigned as CEO and director 11 Aug 2021. Re-elected director Nov 2022. Co-CEO from 28 Jul 2023. Sole representative director in the FY2025 business report.

BS, MS and PhD in Microbiology, Seoul National University

Associate Professor, KAIST Biological Sciences; Assistant Professor, SNU Genetic Engineering Research Institute; Research Assistant Professor, University of Wisconsin

Lee Seung-ho

Former CEO (from Aug 2021); co-CEO with Kim from Jul 2023

Not listed as representative in the FY2025 filing data reviewed.

—

Head of Nomura investment banking in Korea; formerly Morgan Stanley

Jin Seok-min

Managing Director; Head, Novel Biologics Research Institute

—

PhD Neurobiology, Ajou University; MS and BS Biology, Kyung Hee University

Chong Kun Dang (neuro team leader); SNU College of Medicine research assistant professor; NIH fellow

Kim Gyeong-yong

Managing Director; Head, Process Analysis Institute

—

PhD and MS Biochemistry, BS Microbiology, Chungbuk National University

ISU Abxis; LabFrontier

Kim Mi-suk

Managing Director; Head, Business Management HQ

—

PhD, MS and BS Life Sciences, Sookmyung Women's University

Samsung Medical Center; NIH/NCI; National Cancer Center; Korea Institute of Radiological and Medical Sciences

Na O-seong

Managing Director; Osong Plant Head (Aprogen Biologics)

—

MS Chemistry, POSTECH; BS Chemistry, Dongguk University

Aprogen Biologics fill-finish head; Hanmi Pharm; Celltrion (culture and fill-finish)

Kim Jeong-chul

Co-CEO, Aprogen Biologics; affiliate executive and shareholder (0.34%)

———

Park Mi-ryeong

Executive; shareholder (2.05%)

———

Board & Management Changes

DateChangeContext

11 Aug 2021

Kim Jae-seop resigns as CEO and director; Lee Seung-ho appointed CEO

Intended to professionalise management ahead of an IPO [S11]

Nov 2022

Kim Jae-seop re-elected registered director (EGM)

Founder resumes formal board role after the share-price collapse [S11]

28 Jul 2023

Kim appointed co-CEO

Cited need for scientific leadership in licensing talks [S11]

Dec 2024 – Jan 2025

Kim and Kang Jong-soo appointed to the GeoLit Energy (Apton) board; former Aprogen research head Park Mi-jeong appointed CDO; former broadcaster Choi Woong-ki appointed group PR executive

Control of Apton established [S24]

Major Shareholders

HolderStake (%)Basis / date

G-Baise Co., Ltd.

21.80

FY2025 business report

Nexconics Co., Ltd. (related party)

8.04

FY2025

Kim Jae-seop

4.05

FY2025

Park Mi-ryeong

2.05

FY2025

Kim Jeong-chul

0.34

FY2025

Kang Seon-ju

0.06

FY2025

Controlling group total

36.63 (37.66 per Apr 2026 filing)

—

Harvest Rose

14.18

Large-holding report filed 9 Sep 2026.

National Pension Service

1.60

End-2024

Treasury shares

about 5.97

2026

Minority shareholders (49,074 holders)

57.36

FY2025

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlapRelative positioningSource

Trastuzumab biosimilar

Celltrion (Herzuma)

Direct

Marketed in US and EU for years; scale incumbent

[S3]

Trastuzumab biosimilar

Samsung Bioepis (Ontruzant)

Direct

Marketed in US and EU

[S3]

Trastuzumab biosimilar

Amgen (Kanjinti)

Direct

Marketed in US

[S3]

Trastuzumab biosimilar

Pfizer (Trazimera)

Direct

Marketed in US

[S3]

Trastuzumab biosimilar

Viatris/Biocon (Ogivri)

Direct

First US trastuzumab biosimilar

[S3]

Adalimumab biosimilar

Celltrion, Samsung Bioepis, Sandoz, Alvotech, Amgen, Boehringer Ingelheim and others

Direct

Crowded US market since 2023

—

Rituximab biosimilar

Celltrion (Truxima), Pfizer (Ruxience), Amgen (Riabni), Sandoz

Direct

Mature

Background knowledge

CDMO

Lonza (25.6% share, 2023), WuXi Biologics (12.1%), Catalent (10.1%), Samsung Biologics (9.9%), Fujifilm (6.8%), Boehringer Ingelheim (5.9%), AGC Biologics (4.4%)

Direct for antibody DS/DP

Aprogen's share is negligible

[S3]

Korean perfusion and biosimilar peers

Celltrion (250,000L), Samsung Biologics (604,000L)

Capacity comparison

Aprogen claims 360,000L fed-batch-equivalent output

[S3]

Stem-cell mobilisers (GPC-100)

Sanofi (plerixafor, Mozobil); BioLineRx (motixafortide)

Direct for multiple myeloma mobilisation

GPC-100 is Phase 2-complete with fast onset claimed

—

Semiconductor parts / hardfacing / insulation

Fragmented domestic suppliers

Indirect

Not benchmarkable from disclosures

—

Peer Comparison FY2025

MetricAprogen (FY2025)Celltrion (FY2024)Samsung Biologics (FY2024)Aprogen Biologics (FY2025)

Revenue (KRW Bn)

118.0

about 3,557

about 4,547

73.2

Revenue growth (%)

-21.4——8.7

Operating margin (%)

-81.0

about 14

about 29

-82.5

Recent Developments

Coverage runs from about March 2025 to October 2026.

Company Snapshot

$83M

Revenue

625

Employees

1971

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Productivity evidence. The Nov 2024 AP096 clinical run harvested 201.5 kg in a single 2,000L perfusion campaign. The company equates this to six 15,000L fed-batch runs [S3].
  • Regulatory de-risking of the lead asset. Both the FDA (pre-BLA, May 2026) and the EMA indicated AP063 can be filed without a confirmatory Phase 3 [S21][S22].
  • Integrated facility. Osong has 3,000 kg/yr DS capacity and 6.4M lyophilised vials, 60M liquid vials and 80M PFS per year of DP capacity, built at a cost of about KRW 600bn. It holds MFDS specialised-CMO approval (June 2024) [S3][S25].
  • Prior approval experience. GS071 was approved in Japan in 2017 and completed a US Phase 3 [S3].
  • Diversified late-stage optionality via Apton. GPC-100 has completed Phase 2 and holds an FDA Orphan Drug Designation [S34].
  • IP estate. 80 registered patents, including a bispecific platform registered in the US and other major jurisdictions [S3].

Weaknesses

  • Chronic losses. Operating losses of KRW 87–119bn every year from FY2021 to FY2025; FY2025 net loss of KRW 140.6bn [S1].
  • Revenue quality. About 58% of the 2Q26 revenue mix is non-pharma: hardfacing, semiconductor parts, geothermal and insulation [S4].
  • Fixed-cost burden. Parent payroll was 40.6% of separate revenue in FY2025, up from 4.8% in FY2021 [S2].
  • Related-party financing loops. Examples include the circular KRW 70bn transactions of 2018 [S9], the 2025–26 CBs placed with affiliates [S30][S32], and N2Tech's KRW 89bn funding of affiliates [S27].
  • Liquidity. Current ratio of 0.86x in FY2023–FY2024 and cash of only KRW 37.1bn at FY2024 [S3].
  • Delivery record. Repeated failure to meet listing and commercial targets: the 2016 IPO withdrawal [S42], the 2020 merger abandonment [S10], and the 2020 projection of KRW 1tn revenue by 2026 against actual FY2025 revenue of KRW 118bn [S9][S1].

Opportunities

  • FDA/EMA streamlining. Accepting AP063 without Phase 3 could save about KRW 130bn and pull approval forward [S20].
  • Low cost base at scale. A 50% discount target would still be value-accretive on the company's cost claims [S19].
  • Burixafor. A single roughly 120-patient Phase 3 with about a 2-year readout target, plus potential in-vivo CAR-T booster demand [S34].
  • AP209. First-in-human in osteoarthritis (46 patients) with licence-out discussions reported [S37][S31].
  • CDMO demand diversification. Sponsors moving away from China-based CDMOs could favour Osong [S44].
  • PMC-309. Keytruda combination optionality (Phase 1a/1b in Australia) [S29].

Threats

  • Commoditised trastuzumab market. About 84% of the US market is already biosimilar, with five or more incumbents [S3].
  • Dilution overhang. Aprogen Biologics' July 2026 CB alone converts into about 1.5x its issued shares [S32]. Aprogen issued a KRW 20bn CB in September 2026 [S35].
  • Penny-stock and listing-maintenance rules. These forced the 15:1 and 20:1 capital reductions at subsidiaries [S8][S45].
  • Cross-collateralisation. Aprogen Biologics pledged about KRW 63bn of collateral for Aprogen's KRW 45bn borrowing [S32].
  • Controlling-shareholder liquidity needs. G-Baise sold Aprogen shares seven times between 2020 and 2023 [S14] and has borrowed from N2Tech [S27].
  • Regulatory scrutiny. History of FSS rejections of the merger filing [S10]; ongoing press scrutiny of governance [S27][S35].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Mar 2025Aprogen Biologics acquires Montana Fund No. 72 (KRW 32.6bn), gaining control of N2Tech [S26][S27]Adds semiconductor-parts revenue (22% of 2026 mix)
Mar 2025Aprogen Biologics issues 17th CB (KRW 65bn) [S30]Short-term refinancing
17–18 Apr 2025AP063 Phase 3 (APRILIAH) recorded as ended in the EU CTIS [S23]Early termination ahead of regulatory easing
15 May 2025Q1 FY2025 report: revenue KRW 26.7bn (-29.8% YoY), operating loss KRW 22.5bn [S1]Revenue trough
20 May 2025FTC notifies holding-company status effective 1 Jan 2025 [S7]Statutory constraints on group structure
11 Jun 2025IR presentation published (pipeline, Osong, CDMO strategy; about 2027 turnaround) [S3]Main strategic disclosure
19 Jun 2025Apt Neuroscience announces US subsidiary for crypto-asset investment [S43]Diversification outside the core business; governance concern
14 Aug 2025H1 FY2025 report: Q2 revenue KRW 24.2bn, net loss KRW 42.2bn [S1]Weakest quarter
18 Aug 2025PMC-309 in-licensed from PharmAbcine [S29]Immuno-oncology asset
18–21 Aug 2025AP Healthcare stake raised to 71.66% (KRW 317 per share) [S28]Control consolidation
22 Sep 2025Press reports Aprogen Biologics in CDMO discussions with global pharma [S44]CMO pipeline
16 Oct 2025Aprogen Biologics issues 18th CB (KRW 15bn) to Apton at KRW 605 [S30]Intra-group refinancing; total ABL CB balance KRW 115bn
5 Nov 2025Three-pillar strategy announced (biosimilars, new drugs, hybrid CMO) [S31]Strategy restatement
6 Nov 2025AP063 plan restructured to quality/PK; about KRW 130bn savings claimed [S20]Approval path shortened
14 Nov 2025Q3 FY2025 report: revenue KRW 35.6bn, operating loss KRW 22.3bn [S1]Partial revenue recovery
23 Feb 2026Aprogen Biologics (15:1) and Aptochrome (20:1) capital reductions announced [S8]Offsets accumulated deficits; addresses penny-stock delisting rules
23 Mar 2026FY2025 annual report: revenue KRW 118.0bn, operating loss KRW 95.6bn, net loss KRW 140.6bn [S1]Worst net loss on the restated series
20 Apr 2026Controlling-group stake reported at 37.66% [S2]Ownership update
8 May 2026FDA pre-BLA: no confirmatory Phase 3 required for AP063 [S21]Major regulatory de-risking
~May 2026EMA confirms an MAA is possible without Phase 3; ABL shares up about 17% on 14 May [S22]Converges with the FDA view
15 May 2026Q1 FY2026 report: revenue KRW 36.3bn (+35.8% YoY) [S1]N2Tech consolidation effect
~Jun 2026AP209 osteoarthritis study approved by MFDS (46 patients) [S37]First-in-human for an in-house novel biologic
24–29 Jun 2026Apton third-party placements (filings amended) [S36]Funds new business and GPCR stake
1 Jul 2026Aprogen Biologics issues a KRW 50.8bn CB to an affiliate. Conversion shares equal about 1.5x issued shares. ABL pledged about KRW 63bn of collateral for Aprogen's KRW 45bn borrowing. [S32]Overhang and cross-guarantee risk
2 Jul 2026Apton to invest KRW 10bn in GPCR (largest shareholder) [S33]Entry into CAR-T booster and obesity
16 Jul 2026SDS Holdings takes 15% of Apton for KRW 3.5bn [S33]Reciprocal alignment
21 Jul 2026First KRW 3bn GPCR tranche paid [S33]Execution
14 Aug 2026H1 FY2026 report: Q2 revenue KRW 35.5bn (+47.0%), net loss KRW 42.3bn [S1]Top line up, losses persist
~Aug 2026AP209 IRB submitted to Kyung Hee University Hospital [S37]Trial start-up
26 Aug 2026Apton secures global exclusive rights to burixafor (GPC-100); up to KRW 472bn milestones [S34]Late-stage asset added; Aprogen and Apton shares fell 7.7% and 14.0% that day
31 Aug 2026US Phase 3 and approval strategy for GPC-100: about 120 patients, about 2-year readout target, Orphan Drug Designation [S34]Timeline signal
7–9 Sep 2026Aprogen KRW 20bn private CB; ABL KRW 20bn rights issue (about 78% of shares) at KRW 1,574; use of proceeds undetermined [S35]Dilution and related-party criticism
9 Sep 2026Harvest Rose files a 14.18% large-holding report in Aprogen [S2]New major holder
17 Sep 2026Aprogen clinical team mobilised for the GPC-100 Phase 3 (EOP2 meeting with FDA planned) [S34]Execution
21–23 Sep 2026Amended CB and rights-issue filings; subsidiary loan decisions; issuance results filed [S4]Financing completed
7 Oct 2026Press analysis: N2Tech has channelled KRW 89bn (55.9% of its total assets) to group affiliates since the control change; its cash fell 75.5% [S27]Governance and liquidity red flag

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: Pharmaceuticals was KRW 30,900 Mn in 2026.
Aprogen Inc. — Revenue by Segment
Series (KRW Mn)2026
Pharmaceuticals30,900
Hardfacing16,500
Semiconductor equipment parts15,800
Renewable energy7,200
Insulation2,200

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1ETF Shopping, Aprogen earnings page compiling DART quarterly and annual filings (FY2020–2Q26) (etfshopping.com)
  2. S2ETF Shopping, Aprogen company page compiling the FY2025 DART business report (ownership, employees, subsidiaries, pay) (etfshopping.com)
  3. S3Aprogen Inc., IR Presentation, June 2025 (includes FY2021–FY2024 consolidated statements) (file.alphasquare.co.kr)
  4. S4Butler.works, Aprogen (007460) profile (segment mix 2Q26, 5-year figures, market cap, target price, recent filings) (butler.works)
  5. S5Valueline.co.kr, Aprogen income statement and market data (27 Aug 2026) (valueline.co.kr)
  6. S6Investing.com (vn/sa editions), Aprogen KIC Inc (007460) quote pages, Jul–Aug 2026
  7. S7Dealsite, holding-company conversion notice (20 May 2025) (dealsite.co.kr)
  8. S8Dealsite, subsidiaries' capital reductions (23 Feb 2026) (dealsite.co.kr)
  9. S9Asia Economy series on the Aprogen group (31 Jan 2020, 6 Feb 2020, 27 Apr 2020): core.asiae.co.kr articles 2020013110523341720, 2020020616082560033, 2020042714274087560
  10. S10eToday, three-company merger effectively withdrawn (8 Sep 2020) (etoday.co.kr)
  11. S11Asia Economy / Dealsite, Kim Jae-seop returns as co-CEO (28 Jul 2023) (dealsite.co.kr)
  12. S12Bizwatch, inquiry response on control-change financing (18 Aug 2022) (news.bizwatch.co.kr)
  13. S13SBS Biz, Aprogen restructuring and voluntary retirement (3 Mar 2023) (biz.sbs.co.kr)
  14. S14IB Tomato, G-Baise stake and lock-up release (12 Nov 2024) (newstomato.com)
  15. S15Hankyung, Aprogen Biologics rights offering (15 Jan 2024) (hankyung.com)
  16. S16Asia Economy, Aprogen Biologics restructuring (6–7 Mar 2024) (core.asiae.co.kr)
  17. S17IB Tomato, Aprogen Biologics funding from Aprogen (12 Jul 2024) (newstomato.com)
  18. S18Dealsite, AP Healthcare KRW 50bn offering and AP096 co-funding (20 Sep 2024) (dealsite.co.kr)
  19. S19Asia Economy, AP063 global Phase 3 in 19 countries (27 Jul 2023) (core.asiae.co.kr)
  20. S20Finance Scope, AP063 FDA BPD meeting (21 Oct 2024) and AP063 strategy reset (6 Nov 2025) · finance-scope.com
  21. S21Financial News, FDA confirms Phase 3 can be skipped for AP063 (8 May 2026) (fnnews.com)
  22. S22JKN, EMA confirmation reported (14 May 2026) (news.jkn.co.kr)
  23. S23EU CTIS trial record 2023-506975-83-00 (APRILIAH, AP063-003) (ctis.eu)
  24. S24Asia Economy, GeoLit Energy control change and appointments (17 Dec 2024; 10 Jan 2025) · core.asiae.co.kr
  25. S25Hankyung, Aprogen Biologics CDMO progress (19 Jan 2025) (hankyung.com)
  26. S26Dealsite, Aprogen Biologics acquires Montana New Technology Fund No. 72 (28 Mar 2025) (dealsite.co.kr)
  27. S27IB Tomato, N2Tech funds affiliates with KRW 89bn (7 Oct 2026) (newstomato.com)
  28. S28Digital Today AI disclosure, Aprogen raises AP Healthcare stake to 71.66% (Aug 2025) (digitaltoday.co.kr)
  29. S29Digital Today and Bizwatch, PMC-309 licence (Aug 2025) · news.bizwatch.co.kr
  30. S30Dealsite, Aprogen Biologics KRW 15bn CB to Apton (16 Oct 2025) (dealsite.co.kr)
  31. S31Dealsite, Aprogen three-pillar strategy (5 Nov 2025) (dealsite.co.kr)
  32. S32Daum News, Aprogen Biologics KRW 50.8bn CB (1 Jul 2026) (v.daum.net)
  33. S33Financial News and Dealsite, Apton–GPCR investment (2, 16 and 21 Jul 2026) · dealsite.co.kr · fnnews.com
  34. S34Money Today, Dealsite and Asia Economy, GPC-100 rights and Phase 3 plan (26 Aug, 31 Aug, 17 Sep 2026) · dealsite.co.kr · core.asiae.co.kr · mt.co.kr
  35. S35IB Tomato, Aprogen Biologics rights issue and Aprogen CB (9 Sep 2026) (newstomato.com)
  36. S36KnowingAsset, Apton rights-issue filings (24 and 29 Jun 2026) · knowingasset.com
  37. S37MyDailyByte news digest, AP209 IND approval and IRB submission (2026) (mydailybyte.com)
  38. S38CB Insights, Aprogen Medicines / Aprogen KIC profile (cbinsights.com)
  39. S39TheVC, Aprogen, old Aprogen and G-Baise profiles · thevc.kr · thevc.kr
  40. S40Butler.works, Aprogen Biologics (003060) profile (butler.works)
  41. S41Asia Economy, Aprogen applies for designated auditor for KOSPI IPO (31 Mar 2021) (core.asiae.co.kr)
  42. S42eToday, Aprogen backdoor-listing speculation after IPO withdrawal (19 Sep 2016) (etoday.co.kr)
  43. S43Asia Economy, Apt Neuroscience US crypto subsidiary (19 Jun 2025) (view.asiae.co.kr)
  44. S44Dealsite, Aprogen Biologics CDMO capacity and order expansion (23 Sep 2025) (dealsite.co.kr)
  45. S45Daily Pharm, biotech share consolidations amid penny-stock rules (12 Mar 2026) (dailypharm.com)
  46. S46The VC, Aprogen financial and business-model summaries (thevc.kr)
  47. S47MyDailyByte, 007460 quote (26 Sep 2026) (mydailybyte.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.